ArticleMedicine2019

CDK4/6 inhibition versus mTOR blockade as second-line strategy in postmenopausal patients with hormone receptor-positive advanced breast cancer: A network meta-analysis.

Hong-Wei Huang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.